The risks of Tysabri, an effective drug for treating MS, and the risks of MS patients developing progressive multifocal leukoencephalopathy the longer they are on the medication"underscores a central mathematical issue in assessing risks and benefits of medical treatment," comments the Wall Street Journal in the September 9, 2009, issue. Absolute percentages, mathematical models and actuarial calculations all figure in figuring the risks in this Biogen drug that has been on the market for three years.
News and views from Brennemann Library are for the physicians, nurses and allied health professionals at Children's Memorial Hospital to foster the patient care, education, research and advocacy missions of Children's Memorial Hospital, Chicago, Illinois. Articles posted range from those found in mainstream media for lay audiences to those selected from professional, peer-reviewed journals. The Brennemann Blog does not endorse the information found in these articles.
On the right is a selection of recent articles of medical News, E-medicine, Nursing, Pediatrics, Hospitals and Heath Care and Patient Safety.
NEWS
E - MEDICINE
PEDIATRICS
HOSPITALS and HEALTH CARE
text/javascript">